X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Gabby Migliara

Gabby Migliara is a senior manager of public affairs at PhRMA focusing on the cost and value of medicines. She previously worked with the U.S. Census Bureau on marketing and communications for the 2020 Census campaign. Outside the office, Gabby enjoys trying new restaurants, hanging with her cat and exploring DC neighborhoods.

Recent Posts

Why drug importation is bad for Americans

By Gabby Migliara  |    May 12, 2022
Drug importation schemes are dangerous and have significant negative consequences for both individuals and our health care system. Importation refers to when governments or individuals circumvent the...   Read More

ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19

By Gabby Migliara  |    April 28, 2022
Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19. We’ve made...   Read More

Part D 101: Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities

By Gabby Migliara  |    April 27, 2022
In yesterday’s post, we learned how Medicare Part D works for seniors and people with disabilities. Unfortunately, Part D beneficiaries are increasingly facing higher out-of-pocket costs for the...   Read More

Part D 101: Three charts show how the program provides comprehensive prescription drug coverage

By Gabby Migliara  |    April 26, 2022
Medicare Part D provides prescription drug coverage for our nation’s seniors and Americans with disabilities. These beneficiaries can opt to enroll in Part D and pick from a variety of plans offered....   Read More

New analysis confirms hospitals markup prices for oncology therapies

By Gabby Migliara  |    April 21, 2022
A recent study from The Journal of the American Medical Association (JAMA) examined 61 hospitals using data made public under new requirements from a recent price transparency regulation. The...   Read More

Veterans Affairs 101: Three charts show how the VA system differs from Medicare

By Gabby Migliara  |    March 11, 2022
The U.S. Department of Veterans Affairs (VA) primarily provides medical coverage for veterans who have experienced service-related disabilities. Its unique system was developed to meet the targeted...   Read More

ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development

By Gabby Migliara  |    October 18, 2021
A new study from economists at the University of Chicago examined the impact that government price-setting policies for medicines, like those in H.R. 3, could have if implemented. The economists...   Read More

New report: To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and the health system

By Gabby Migliara  |    October 14, 2021
A new study from the Employee Benefit Research Institute (EBRI) compared the difference in price for 72 physician-administered outpatient medicines – representing 73% of medicine spending – depending...   Read More

PhRMA releases 2021 industry profile

By Gabby Migliara  |    September 20, 2021
Today, PhRMA released its 2021 Biopharmaceutical Industry Profile, a resource that highlights the latest from the industry on innovation, access and affordability. The Profile has told the story of...   Read More

What they’re saying: Patient advocates want to protect Medicare from government interference

By Gabby Migliara  |    August 24, 2021
For seniors and people with disabilities, Medicare Parts B and D provide important access to lifesaving medicines. Unfortunately, some in Congress are proposing changes to Medicare under the guise of...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates